Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 52Other hematologic neoplasm 27Dermatologic 2CNS 2Myeloid 1Classical hematology 1Breast 1

Conditions

Neurologic Manifestations 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 59Radiotherapy 37Magnetic Resonance Spectroscopy 32Radiosurgery 27Specimen Handling 23Cyclophosphamide 21pembrolizumab 20Nivolumab 20Radiation 17Carboplatin 12Biopsy 12Bevacizumab 11Vincristine 10Ipilimumab 10Cisplatin 10X-Rays 9Lomustine 8Irinotecan 8Immunoglobulin G 8Etoposide 8trametinib 7Disulfides 7AZD 6244 7pertuzumab 6atezolizumab 6abemaciclib 6Topotecan 6Proton Therapy 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × ibrutinib × CNS × Clear all
NCT03535350 2025-09-30

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
36 enrolled
CNS

Brain Neoplasms, Glioblastoma

NCT04446962 2025-09-25

LOC-R01

Institut Curie

Phase 1/2 Active not recruiting
118 enrolled
CNSLymphoid

Lymphoma, Neurologic Manifestations, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡